Key Takeaways
- • Eli Lilly & Co. has agreed to acquire CrossBridge Bio Inc., a venture-backed pre-clinical biotechnology firm, in a deal valued at up to $300 million, announced on April 14, 2026.
- • CrossBridge Bio, based in Houston, is developing innovative drug delivery technologies to transport chemotherapy directly to cancer cells, representing a strategic oncology expansion for Eli Lilly.
- • The acquisition was facilitated by law firm Cooley LLP, which advised CrossBridge Bio on the transaction.
- • The deal underscores Eli Lilly's continued investment in the Houston biotech ecosystem, following multiple significant acquisitions and partnerships in the region.
Summary
Eli Lilly & Co. announced on Tuesday, April 14, 2026, that it has agreed to acquire CrossBridge Bio Inc., a Houston-based, venture-backed pre-clinical biotechnology company, in a transaction valued at up to $300 million. The deal was facilitated by Cooley LLP, which advised CrossBridge Bio throughout the negotiation and acquisition process.
CrossBridge Bio specializes in developing proprietary technologies for targeted cancer drug delivery, specifically engineering methods to transport chemotherapy directly to cancer cells. This specialized focus on oncology therapeutics aligns with Eli Lilly's broader strategic priorities in the cancer treatment space and represents an opportunity to integrate novel delivery mechanisms into the pharmaceutical giant's existing oncology portfolio.
The acquisition reflects Eli Lilly's strategic commitment to the Houston biotech market. The pharmaceutical company has executed multiple significant transactions and partnerships in the Houston region, positioning itself as a major player in the regional life sciences landscape. By acquiring CrossBridge Bio, Eli Lilly gains access to pre-clinical technology and intellectual property that could enhance its competitive positioning in precision oncology and targeted drug delivery—areas of substantial clinical and commercial importance.
The $300 million valuation suggests meaningful investor confidence in CrossBridge Bio's technology platform, particularly given its pre-clinical stage. For venture investors and limited partners backing CrossBridge Bio, the transaction provides a liquidity event and validation of the company's therapeutic approach through acquisition by a top-tier pharmaceutical company.
CrossBridge Bio specializes in developing proprietary technologies for targeted cancer drug delivery, specifically engineering methods to transport chemotherapy directly to cancer cells. This specialized focus on oncology therapeutics aligns with Eli Lilly's broader strategic priorities in the cancer treatment space and represents an opportunity to integrate novel delivery mechanisms into the pharmaceutical giant's existing oncology portfolio.
The acquisition reflects Eli Lilly's strategic commitment to the Houston biotech market. The pharmaceutical company has executed multiple significant transactions and partnerships in the Houston region, positioning itself as a major player in the regional life sciences landscape. By acquiring CrossBridge Bio, Eli Lilly gains access to pre-clinical technology and intellectual property that could enhance its competitive positioning in precision oncology and targeted drug delivery—areas of substantial clinical and commercial importance.
The $300 million valuation suggests meaningful investor confidence in CrossBridge Bio's technology platform, particularly given its pre-clinical stage. For venture investors and limited partners backing CrossBridge Bio, the transaction provides a liquidity event and validation of the company's therapeutic approach through acquisition by a top-tier pharmaceutical company.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.